Kadcyla

Trastuzumab emtansine, the active ingredient in Kadcyla, is an antibody‑drug conjugate presented as a sterile powder for reconstitution for intravenous injection. It is indicated for the treatment of HER2‑positive metastatic breast cancer and HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma in adult patients.

GNH USA supplies Kadcyla as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to oncology centres, hospitals and pharmacies worldwide under strict quality standards and regulatory compliance. The company ensures reliable cold‑chain logistics and supports clinical teams with documentation for import and distribution.

Kadcyla is used in HER2‑targeted therapy for certain advanced cancers.

- Metastatic HER2‑positive breast cancer: improves overall survival and disease control. - HER2‑positive gastric adenocarcinoma: provides clinical benefit in previously treated patients. - HER2‑positive gastro‑esophageal junction adenocarcinoma: extends progression‑free interval in advanced disease.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate gastrointestinal upset. - Thrombocytopenia: reduced platelet counts requiring monitoring. - Anemia: decreased red blood cell levels causing weakness. - Elevated liver enzymes: transient increases in ALT/AST. - Alopecia: hair thinning or loss during treatment.

Serious or Rare Side Effects: - Interstitial lung disease: breathing difficulties that may be life‑threatening. - Cardiac dysfunction: reduced left ventricular ejection fraction. - Severe hepatic toxicity: marked elevation of liver enzymes or hepatitis. - Hemorrhage: significant bleeding events. - Infusion‑related reactions: fever, chills, or hypotension during administration.

Kadcyla requires careful monitoring and specific safety measures.

- Cardiac monitoring: assess left ventricular ejection fraction before and during treatment. - Hepatic function: monitor liver enzymes regularly. - Bleeding risk: evaluate platelet counts and avoid concomitant anticoagulants if possible. - Pregnancy and lactation: avoid use; discuss risks with physician. - Infusion reactions: administer premedication and monitor during infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kadcyla may interact with other medicines; some combinations should be avoided while others need close observation.

Major Interactions (Avoid): - Concurrent anthracyclines: increased cardiotoxicity. - Strong CYP3A4 inhibitors: may increase exposure to the cytotoxic payload. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk. - Other HER2‑targeted agents: additive toxicity. - Hepatotoxic drugs: monitor liver function closely.